Cohort Highlights
>15 Autoimmunte Results
Agents included: >15 autoimmune lab results including antinuclear antibody (ANA) tests, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and more
>23,000 Cohort
Cohort Size: >23K consented Autoimmune disease patients including RA, Lupus, MS, Psoriasis, Hashimoto’s and many more
~ 15yrs lookback
Average patient EHR history: ~15yrs lookback including diagnoses, lab results, prescriptions and much more
Longitudinal Clinical Insights
Et odi iligenduci rem rehendi tibusa quam voluptaturi volupta assum untiasped et verchitatus rem atibus aut perspelia volorro elique dolupta tibus, aut aute nonseque exceptae. Nequia quis dolorum recerum laborrum quibus comniantibus doluptatur?
Min etusdae pratem fugit, tem fugiate mporibuscium niende sequiam qui de molorehento illia nobis sunt hariae re nonsequisse ni coris eictest otasped que estrum, et qui comnisti corrum quam harum soluptasit, sentus.
Research Insights
Inflammatory Bowel Disease (IBD), including Crohn’s disease and Ulcerative Colitis impacts millions of people in the US. Conventional treatments are currently limited to reducing inflammation, however personalized treatment can offer options to treat the disease directly. Using data from the Helix Research Network, Helix scientists recently presented an analysis at the ASHG conference on the genetics of Crohn’s disease, and in particular the NOD2 gene where mutations in the gene have been associated with Crohn’s disease and other conditions.
